Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: A Systemic Review and Meta-Analysis

Authors

Haoran Zhang
Ai Zhong
Junjie Chen

Publication Date

1-1-2023

Journal

Skin Research & Technology

Abstract

BACKGROUND: To evaluate the immune checkpoint inhibitors (CPI) for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC).

MATERIALS AND METHODS: A meta-analysis was conducted, and the efficacy and safety of CPI were assessed.

RESULTS: A total of 13 studies with 980 patients were included. The pooled objective response rate (ORR) and disease control rate were 47.2% and 64.4%, separately. In addition, patients with primary tumor located in head and neck (odds ratio [OR]: 0.374, 95% confidence interval [CI]: 0.219-0.640, p < 0.001) and positive expression of programmed death ligand 1 (OR: 0.364, 95% CI: 0.158-0.842, P = 0.018) had superior ORR during CPI treatment. The incidence of progression free survival at 6 and 12 months was 59.3% and 52.8%, and 80.6% and 76.4% for overall survival. As for safety, the overall incidence of adverse events with all grades and 3-4 grade was 76.9% and 20.2%.

CONCLUSIONS: Our systematic review confirmed the satisfying efficacy and acceptable toxicity of CPI for advanced CSCC.

Keywords

cemiplimab, cutaneous squamous cell carcinoma, immune checkpoint inhibitors, meta‐analysis, nivolumab, pembrolizumab

Comments

Supplementary Material

PMID: 36329570

DOI

10.1111/srt.13229

PMID

36329570

PMCID

PMC9838749

PubMedCentral® Posted Date

November 2022

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes